Intellia Therapeutics, Inc.
NTLA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.77 | 0.22 | 0.12 | 0.44 |
| FCF Yield | -4.04% | -10.26% | -20.34% | -7.26% |
| EV / EBITDA | -18.75 | -8.55 | -6.16 | -9.03 |
| Quality | ||||
| ROIC | -12.98% | -13.25% | -13.24% | -12.40% |
| Gross Margin | -472.84% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.76 | 0.98 | 1.30 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.58% | -0.11% | -5.19% | 3.55% |
| Free Cash Flow Growth | 22.96% | 33.28% | -73.67% | -0.07% |
| Safety | ||||
| Net Debt / EBITDA | 0.99 | 0.50 | 0.06 | -0.16 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 57.04 | 71.73 | 56.86 | 59.54 |